alendronate has been researched along with Complication, Postoperative in 27 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of an anti-osteoporosis regimen that combined a bisphosphonate agent (alendronate sodium) with the osteogenic stimulus of mechanical loading, 25 HTRs were randomly assigned either to a group that received alendronate (10 mg/day) for 6 months (ALEN; n = 8), a group that received alendronate (10 mg/day) and performed specific resistance exercises for 6 months (ALEN + TRN; n = 8) or to a non-intervention control group (CONTR; n = 9)." | 9.10 | Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. ( Aranda, J; Braith, RW; Fulton, MN; Hill, JA; Magyari, PM; Walker, T, 2003) |
| "To determine the efficacy of an anti-osteoporosis regimen that combined a bisphosphonate agent (alendronate sodium) with the osteogenic stimulus of mechanical loading, 25 HTRs were randomly assigned either to a group that received alendronate (10 mg/day) for 6 months (ALEN; n = 8), a group that received alendronate (10 mg/day) and performed specific resistance exercises for 6 months (ALEN + TRN; n = 8) or to a non-intervention control group (CONTR; n = 9)." | 5.10 | Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. ( Aranda, J; Braith, RW; Fulton, MN; Hill, JA; Magyari, PM; Walker, T, 2003) |
| "This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda." | 3.70 | Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case. ( Badhwar, V; Campisi, P; Morin, S; Trudel, JL, 1999) |
| "Osteoporosis and osteomalacia have been observed after gastrectomy and appear to be caused by reduced food intake and absorption, and steatorrhea." | 2.82 | Metabolic bone disorders after gastrectomy: inevitable or preventable? ( Aoyama, T; Atsumi, Y; Rino, Y; Yamada, T; Yukawa, N, 2022) |
| "Bisphosphonates inhibit bone resorption and may reduce this loss in BMD." | 2.80 | Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients. ( Jaroma, AV; Kröger, H; Soininvaara, TA, 2015) |
| "Alendronate-treated patients sustained less bone loss at the spine than those in the reference group, and both intervention groups sustained less bone loss at the hip than the reference group." | 2.71 | Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. ( Addesso, V; Lo, SH; Mancini, D; Maybaum, S; McMahon, DJ; Namerow, PB; Pardi, S; Shane, E; Staron, RB; Zucker, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 13 (48.15) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Morita, A | 1 |
| Kobayashi, N | 1 |
| Choe, H | 1 |
| Ike, H | 1 |
| Tezuka, T | 1 |
| Higashihira, S | 1 |
| Inaba, Y | 1 |
| Rino, Y | 1 |
| Aoyama, T | 1 |
| Atsumi, Y | 1 |
| Yamada, T | 1 |
| Yukawa, N | 1 |
| Meunier, A | 1 |
| Palm, L | 1 |
| Aspenberg, P | 1 |
| Schilcher, J | 1 |
| Farias, DS | 1 |
| Zen Filho, EV | 1 |
| de Oliveira, TF | 1 |
| Tinôco-Araújo, JE | 1 |
| Sampieri, MB | 1 |
| Antunes, HS | 1 |
| Santos, PS | 1 |
| Atik, OS | 1 |
| Oztürk, AM | 2 |
| Kunat, C | 1 |
| Cetinkaya, M | 1 |
| Kaptan, Y | 1 |
| Jaroma, AV | 1 |
| Soininvaara, TA | 2 |
| Kröger, H | 1 |
| Cankaya, D | 1 |
| Tabak, Y | 1 |
| Gunay, MC | 1 |
| Arabmotlagh, M | 1 |
| Pilz, M | 1 |
| Warzecha, J | 1 |
| Rauschmann, M | 1 |
| Iglesias, P | 1 |
| Castro, JC | 1 |
| Abreu, C | 1 |
| Díez, JJ | 1 |
| Voss, PJ | 1 |
| Joshi Oshero, J | 1 |
| Kovalova-Müller, A | 1 |
| Veigel Merino, EA | 1 |
| Sauerbier, S | 1 |
| Al-Jamali, J | 1 |
| Lemound, J | 1 |
| Metzger, MC | 1 |
| Schmelzeisen, R | 1 |
| Ghazali, N | 1 |
| Collyer, JC | 1 |
| Tighe, JV | 1 |
| Conte-Neto, N | 1 |
| Bastos, Ade S | 1 |
| Spolidorio, LC | 1 |
| Chierici Marcantonio, RA | 1 |
| Marcantonio, E | 1 |
| Shane, E | 2 |
| Cohen, A | 1 |
| Stein, EM | 1 |
| McMahon, DJ | 2 |
| Zhang, C | 1 |
| Young, P | 1 |
| Pandit, K | 1 |
| Staron, RB | 2 |
| Verna, EC | 1 |
| Brown, R | 1 |
| Restaino, S | 1 |
| Mancini, D | 2 |
| Koc, M | 1 |
| Tuglular, S | 1 |
| Arikan, H | 1 |
| Ozener, C | 1 |
| Akoglu, E | 1 |
| Jurvelin, JS | 1 |
| Miettinen, HJ | 1 |
| Suomalainen, OT | 1 |
| Alhava, EM | 1 |
| Kröger, PJ | 1 |
| Braith, RW | 1 |
| Magyari, PM | 1 |
| Fulton, MN | 1 |
| Aranda, J | 1 |
| Walker, T | 1 |
| Hill, JA | 1 |
| Jeffery, JR | 1 |
| Leslie, WD | 1 |
| Karpinski, ME | 1 |
| Nickerson, PW | 1 |
| Rush, DN | 1 |
| Nehme, A | 1 |
| Maalouf, G | 1 |
| Tricoire, JL | 1 |
| Giordano, G | 1 |
| Chiron, P | 1 |
| Puget, J | 1 |
| Addesso, V | 1 |
| Namerow, PB | 1 |
| Lo, SH | 1 |
| Zucker, M | 1 |
| Pardi, S | 1 |
| Maybaum, S | 1 |
| Lindsay, R | 1 |
| SoRelle, R | 1 |
| Huang, RC | 1 |
| Khan, SN | 1 |
| Sandhu, HS | 1 |
| Metzl, JA | 1 |
| Cammisa, FP | 1 |
| Zheng, F | 1 |
| Sama, AA | 1 |
| Lane, JM | 1 |
| Atamaz, F | 1 |
| Hepguler, S | 1 |
| Karasu, Z | 1 |
| Kilic, M | 1 |
| Tokat, Y | 1 |
| Yaffe, A | 1 |
| Iztkovich, M | 1 |
| Earon, Y | 1 |
| Alt, I | 1 |
| Lilov, R | 1 |
| Binderman, I | 1 |
| Campisi, P | 1 |
| Badhwar, V | 1 |
| Morin, S | 1 |
| Trudel, JL | 1 |
| Schwarz, EM | 1 |
| Benz, EB | 1 |
| Lu, AP | 1 |
| Goater, JJ | 1 |
| Mollano, AV | 1 |
| Rosier, RN | 1 |
| Puzas, JE | 1 |
| Okeefe, RJ | 1 |
| Cruz, DN | 1 |
| Brickel, HM | 1 |
| Wysolmerski, JJ | 1 |
| Gundberg, CG | 1 |
| Simpson, CA | 1 |
| Kliger, AS | 1 |
| Lorber, MI | 1 |
| Basadonna, GP | 1 |
| Friedman, AL | 1 |
| Insogna, KL | 1 |
| Bia, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty[NCT04167163] | Phase 4 | 58 participants (Actual) | Interventional | 2020-01-10 | Active, not recruiting | ||
| Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation[NCT00297830] | Phase 2/Phase 3 | 111 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant[NCT00580047] | 59 participants (Actual) | Interventional | 2003-12-01 | Completed | |||
| Prevention of Osteoporosis After Cardiac Transplantation[NCT00000412] | Phase 3 | 149 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 0.28 |
| Placebo Zoledronic Acid and Active Alendronate | -0.57 |
| Reference Group | -3.3 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 1.98 |
| Placebo Zoledronic Acid and Active Alendronate | -0.45 |
| Reference Group | -2.6 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 0.39 |
| Placebo Zoledronic Acid and Active Alendronate | -0.21 |
| Reference Group | -2.2 |
Compare compliance where a study coordinator interviewed patients as to how often they missed the once a week oral alendronate, missed taking calcium and vitamin D supplementation, or missed the once a year IV Reclast. (NCT00580047)
Timeframe: 24 months
| Intervention | percentage of compliance (Number) |
|---|---|
| Intravenous Bisphosphonate Post Transplantation | 100 |
| Oral Bisphosphonate Post Transplantation | 80 |
| Placebo Group Post Transplantation | 80 |
Posterior Anterior (PA) spine bone density was measured by dual energy x-ray absorptiometry (DXA) at baseline and 24 months post transplant. The percentage change in the PA spine bone density was then compared from baseline to 24 months post transplant. (NCT00580047)
Timeframe: 24 months
| Intervention | percentage of change of bone density (Number) |
|---|---|
| Intravenous Bisphosphonate Post Transplantation | 8.1 |
| Oral Bisphosphonate Post Transplantation | 6.6 |
| Placebo Group Post Transplantation | 6.5 |
1 review available for alendronate and Complication, Postoperative
| Article | Year |
|---|---|
Metabolic bone disorders after gastrectomy: inevitable or preventable?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; F | 2022 |
12 trials available for alendronate and Complication, Postoperative
| Article | Year |
|---|---|
Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; B | 2020 |
Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Density Conservation Agents; | 2015 |
Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Alendronate; Arthroplasty, Replacement, H | 2009 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Alendronate increases bone mineral density in long-term renal transplant recipients.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Calcitriol; Drug Therapy, Combination; Fem | 2002 |
Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Resor | 2002 |
Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients.
Topics: Alendronate; Bone Density; Exercise Therapy; Female; Glucocorticoids; Graft Rejection; Heart Transpl | 2003 |
Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
Topics: Adult; Alendronate; Azathioprine; Bone Density; Bone Resorption; Calcitriol; Calcium Channel Agonist | 2003 |
[Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study].
Topics: Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Calcium; Double-Blind Method; Female; Hum | 2003 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur; Fractures, Bone; | 2006 |
Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium; Crea | 2002 |
14 other studies available for alendronate and Complication, Postoperative
| Article | Year |
|---|---|
Antiresorptive treatment and talar collapse after displaced fractures of the talar neck: a long-term follow-up of 19 patients.
Topics: Adolescent; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Fem | 2021 |
Clinical and image findings in bisphosphonate-related osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Debridement; Diphospho | 2013 |
Do atypical femoral fractures in patients with prolonged alendronate treatment heal?
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Frac | 2014 |
Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, | 2015 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans | 2012 |
Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2012 |
Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera.
Topics: Aged, 80 and over; Alendronate; Aspirin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone De | 2013 |
Long-term treatment with alendronate increases the surgical difficulty during simple exodontias - an in vivo observation in Holtzman rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Male; Operative Time; Postoperative Complica | 2012 |
Bone loss after cardiac transplantation.
Topics: Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Collagen; Collagen Type I; Fract | 2004 |
Two markers complement each other in identifying risk.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Alendronate; Biomarkers; C-Reactive Protein; Calcitr | 2004 |
Alendronate inhibits spine fusion in a rat model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Transplantation; Contraindications; Gra | 2005 |
Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Diseases; | 1997 |
Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.
Topics: Adult; Alendronate; Cathartics; Colectomy; Colonoscopy; Crohn Disease; Drug Combinations; Enema; Fem | 1999 |
Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
Topics: Alendronate; Animals; Arthritis; Arthroplasty; Cell Division; Disease Models, Animal; Female; Male; | 2000 |